GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

eFFECTOR Therapeutics EFTR · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 6 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

eFFECTOR Therapeutics — daily EFTR Delayed
Market value
$3,760
Last close × shares
Volume
331
Shares, 6 Nov 2026

About eFFECTOR Therapeutics

Its shares trade under the ticker EFTR. It has been listed since 8 January 2021. In the fiscal year to 31 December 2022, it reported revenue of $3.6m and a net loss of $12.9m. At that date it held total assets of $29.1m and shareholders' equity of $3.9m.

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). The company is headquartered in Solana Beach, California. The company went IPO on 2021-01-08. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The firm uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Figures and description from our data supplier, not checked against the company's own report.

More about eFFECTOR Therapeutics →

How it makes its money

Revenue, year to 31 Dec 2021

  • Grant revenue member. $1.4m · 100.0%

Latest on eFFECTOR Therapeutics

Our reporting

We have not reported on eFFECTOR Therapeutics yet.

Next results

17 Nov 2026

Due on 17 Nov 2026. Analysts expect earnings of -6.40 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is eFFECTOR Therapeutics's ticker?

eFFECTOR Therapeutics trades as EFTR on its US listing, under ISIN US28202V2079.

What was eFFECTOR Therapeutics's last closing price?

0.00 on 6 Nov 2026. The figure is in USD and is never converted.

When does eFFECTOR Therapeutics next report results?

Results are expected on 17 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.